Massive 8-Million-Person study reveals who gets hit hardest by COVID
NCT ID NCT06085924
Summary
This study analyzed the health records of over 8 million people in Taiwan to understand the real-world burden of COVID-19. Researchers looked at who was most likely to be hospitalized, need intensive care, or have a fatal outcome. They also compared outcomes for patients who received the antiviral drug Paxlovid (nirmatrelvir/ritonavir) against those who did not.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer Taiwan
Taipei, Taiwan
Conditions
Explore the condition pages connected to this study.